Vertex Pharmaceuticals
VRTX
Market cap $115B

455.45 USD

-4.61

1.00%

At close Jun 13, 4:00 PM EDT

After hours

455.38

-0.07

0.02%

1 day

-1.00%

5 days

1.04%

1 month

5.43%

3 months

-9.44%

6 months

-1.79%

Year to date

12.25%

1 year

-4.92%

5 years

70.09%

10 years

268.79%

About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Employees: 6,100

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

63% more first-time investments, than exits

New positions opened: 205 | Existing positions closed: 126

63% more funds holding in top 10

Funds holding in top 10: 16 [Q4 2024] → 26 (+10) [Q1 2025]

29% more call options, than puts

Call options by funds: $771M | Put options by funds: $596M

20% more capital invested

Capital invested by funds: $95.5B [Q4 2024] → $114B (+$18.8B) [Q1 2025]

10% more repeat investments, than reductions

Existing positions increased: 625 | Existing positions reduced: 566

3% more funds holding

Funds holding: 1,534 [Q4 2024] → 1,580 (+46) [Q1 2025]

0.22% more ownership

Funds ownership: 91.6% [Q4 2024] → 91.81% (+0.22%) [Q1 2025]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$423

7%

downside

Avg. target

$493

8%

upside

High target

$567

24%

upside

7 analyst ratings

3 positive

43%

4 neutral

57%

0 negative

0%

RBC Capital Brian Abrahams	7%downside $423	Sector Perform Maintained	6 May 2025
Scotiabank Greg Harrison	3%downside $442	Sector Perform Maintained	6 May 2025
Morgan Stanley Matthew Harrison	2%upside $464	Equal-Weight Maintained	6 May 2025
JP Morgan Jessica Fye	13%upside $515	Overweight Maintained	6 May 2025
Cantor Fitzgerald Carter Gould	17%upside $535	Overweight Reiterated	6 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 13 articles about VRTX published over the past 30 days

24/7 Wall Street

3 Monster Stocks to Confidently Own for the Next 10 Years

Buy-and-hold investing is a time-tested strategy that rewards patience and discipline.

3 Monster Stocks to Confidently Own for the Next 10 Years

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ET Company Participants David M. Altshuler - Executive VP & Chief Scientific Officer Reshma Kewalramani - CEO, President & Director Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Good afternoon, everyone.

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year's E.

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

Zacks Investment Research

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

The Motley Fool

3 No-Brainer Healthcare Stocks to Buy in June

A new month has arrived. Investors now have a fresh opportunity to buy great stocks.

3 No-Brainer Healthcare Stocks to Buy in June

The Motley Fool

4 Monster Stocks to Buy and Hold for the Next Decade

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising macroeconomic uncertainties, and geopolitical challenges, have weighed on overall investor sentiment.

4 Monster Stocks to Buy and Hold for the Next Decade

The Motley Fool

2 Top Stocks to Buy Right Now

Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the uncertain near-term economic outlook. Even with these issues, though, stocks are likely to produce superior returns to most other assets over the next decade, as they have consistently done in the past.

2 Top Stocks to Buy Right Now

Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Bernstein 41st Annual Strategic Decisions Conference May 30, 2025 8:00 AM ET Company Participants Reshma Kewalramani - President & CEO Conference Call Participants Will Pickering - Bernstein Will Pickering All right. Well, I think we can get started.

Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

The Motley Fool

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

The three major indexes slid in March and April as investors worried about the impact of President Donald Trump's import tariffs on the economy -- but in recent weeks, optimism about lower, more manageable tariff levels has grown. Trump struck a deal with the U.K. and has signed an initial agreement with China, signs that the impact of tariffs may be limited.

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

The Motley Fool

3 Top Growth Stocks to Buy in the Second Half of 2025

Believe it or not, but we're not far away from being halfway through the year. Time flies when you're having fun -- and when you're not having fun, too.

3 Top Growth Stocks to Buy in the Second Half of 2025

See News Rankings

Charts implemented using Lightweight Charts™